<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11461069</article-id><article-id pub-id-type="pmc">2364053</article-id><article-id pub-id-type="pii">6691878</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.1878</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>A phase II study of the bispecific antibody MDX-H210 (anti-HER2 &#x000d7; CD64) with GM-CSF in HER2+ advanced prostate cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>James</surname><given-names>N D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Atherton</surname><given-names>P J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Howie</surname><given-names>A J</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tchekmedyian</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Curnow</surname><given-names>R T</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label>CRC Institute for Cancer Studies, University of Birmingham, Birmingham, B15 2TA, UK</aff><aff id="aff2"><label>2</label>Department of Pathology, University of Birmingham, Birmingham, B15 2TT, UK</aff><aff id="aff3"><label>3</label>Pacific Shores Medical Group, Long Beach, CA, 90813, USA</aff><aff id="aff4"><label>4</label>Medarex Inc, New Jersey, USA</aff><pub-date pub-type="ppub"><month>07</month><year>2001</year></pub-date><volume>85</volume><issue>2</issue><fpage>152</fpage><lpage>156</lpage><history><date date-type="received"><day>12</day><month>04</month><year>2000</year></date><date date-type="rev-recd"><day>08</day><month>01</month><year>2001</year></date><date date-type="accepted"><day>19</day><month>01</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>The proto-oncogene HER2 presents a novel therapeutic target. We report results in 25 patients with HER2+ advanced prostate cancer treated with the bispecific antibody MDX-H210 15&#x02008;&#x003bc;g m<sup>&#x02212;2</sup>by intravenous infusion plus GM-CSF 5&#x02008;&#x003bc;g&#x02008;kg<sup>&#x02212;1</sup>day<sup>&#x02212;1</sup>by subcutaneous injection for 4 days repeated weekly for 6 weeks. Patients with stable disease or better received further cycles of treatment until disease progression or study withdrawal. 1 patient received no treatment and 4 received less than 1 cycle and are included in the toxicity analysis only. Median duration of follow up was 105+ (range 21&#x02013;188) days. Toxicity was generally NCI-CTG 0&#x02013;2. There were 2 grade 4 adverse events (heart failure and dyspnoea) and 1 grade 3 event (allergic reaction) resulting in discontinuation of the study medication. There were 9 further grade 3 events not resulting in trial withdrawal. There were no treatment-related deaths. 7/20 (35&#x00025;) evaluable patients had a &#x0003e;50&#x00025; PSA response of median duration 128 (range 71&#x02013;184+) days. 7/12 (58&#x00025;) patients with evaluable pain had improvements in pain scores. The PSA relative velocity on therapy decreased in 15/18 (83&#x00025;) assessable patients compared to pre-study. GM-CSF and MDX-H210 is active in hormone refractory prostate carcinoma with acceptable toxicity; further studies are warranted. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>prostate cancer</kwd><kwd>bispecific antibody</kwd><kwd>GM-CSF</kwd><kwd>HER2</kwd><kwd>immunotherapy</kwd></kwd-group></article-meta></front></article>


